| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEFR14A |
| Amendment Flag | true |
| Amendment Description | EXPLANATORY NOTEDue to a printer error, the Definitive Proxy Statement of Emergent BioSolutions Inc. (the “Company”) that was filed with the Securities and Exchange Commission on April 14, 2023 inadvertently omitted the full text of Appendices A and B. Accordingly, the Company is filing this Definitive Revised Proxy Statement to include the full text of Appendix A, Definitions and Reconciliations of Non-GAAP to GAAP Financial Measures, and Appendix B, Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan. The correct version of the Definitive Proxy Statement was mailed to the Company’s stockholders and is available for online access on the websites set forth in the Definitive Proxy Statement. |
| Entity Information [Line Items] | |
| Entity Registrant Name | Emergent BioSolutions Inc. |
| Entity Central Index Key | 0001367644 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | PAY VS. PERFORMANCE DISCLOSURE The table set forth below summarizes information to show the relationship between NEO compensation and certain financial performance measures for fiscal years 2020, 2021 and 2022. This information is provided in accordance with Section 95 3(a) of the Dod ank Wall Street Reform an S-K. Fiscal Summary (1) Compensation (2) Average Non-PEO (3) Average Non-PEO (2)(3) Value of Initial Net Income in millions ) (5) Total in millions) (5) Total Peer Group (4) (a) (b) (c) (d) (e) (f) (g) (h) (i) 2022 $ 7,578,573 $ 508,270 $ 3,393,116 $ 951,561 $ 21.89 $ 140.85 $ (223.8 ) $ 1,120.9 2021 $ 6,932,076 $ 532,388 $ 2,469,172 $ 192,682 $ 80.57 $ 121.80 $ 230.9 $ 1,792.7 2020 $ 5,569,978 $ 10,223,966 $ 2,457,336 $ 5,035,083 $ 166.08 $ 108.63 $ 305.1 $ 1,555.4 (1) Mr. Kramer was our principal executive officer (PEO) for each of 2022, 2021 and 2020. (2) The dollar amounts reported in the “Compensation Actually Paid to PEO” column and the “Average Compensation Non-PEO non-PEO S-K. (3) The non-PEO NEOs for 2022 were Mr. Lindahl, Mr. Havey, Ms. Fox and Mr. Saran, our former Chief Strategy and Development Officer, and for each of 2021 and 2020 the non-PEO NEOs were Mr. El-Hibri, Mr. Lindahl, Mr. Havey and Mr. Saran. Supplemental tables reconciling compensation reported in our summary compensation table to CAP for the average of our non-PEO NEOs is provided below. (4) Peer Group reflects published data for the S&P Biotechnology Index. (5) Net income (loss) and Total Revenues for each year shown, as disclosed in the company’s annual report on Form 10-K | ||
| Company Selected Measure Name | Total Revenues | ||
| Named Executive Officers, Footnote [Text Block] | The non-PEO NEOs for 2022 were Mr. Lindahl, Mr. Havey, Ms. Fox and Mr. Saran, our former Chief Strategy and Development Officer, and for each of 2021 and 2020 the non-PEO NEOs were Mr. El-Hibri, Mr. Lindahl, Mr. Havey and Mr. Saran. | ||
| Peer Group Issuers, Footnote [Text Block] | Peer Group reflects published data for the S&P Biotechnology Index. | ||
| PEO Total Compensation Amount | $ 7,578,573 | $ 6,932,076 | $ 5,569,978 |
| PEO Actually Paid Compensation Amount | $ 508,270 | 532,388 | 10,223,966 |
| Adjustment To PEO Compensation, Footnote [Text Block] | PEO SCT to CAP Reconciliation Fiscal Year Reported Summary Reported Value of Equity Award Compensation 2022 $ 7,578,573 $ (6,231,882 ) $ (838,421 ) $ 508,270 2021 $ 6,932,076 $ (4,998,767 ) $ (1,400,921 ) $ 532,388 2020 $ 5,569,978 $ (3,442,423 ) $ 8,096,411 $ 10,223,966 PEO Equity Award Adjustment Reconciliation Fiscal Year Year-End Year-over-Year Equity Awards Fair Value Year Year-over- the Covered Year-end Fair Value of Total 2022 $ 1,391,610 $ (1,603,115 ) $ — $ (626,916 ) $ — $ — $ (838,421 ) 2021 $ 1,869,759 $ (3,301,247 ) $ — $ 30,567 $ — $ — $ (1,400,921 ) 2020 $ 5,854,355 $ 1,898,642 $ — $ 343,414 $ — $ — $ 8,096,411 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 3,393,116 | 2,469,172 | 2,457,336 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 951,561 | 192,682 | 5,035,083 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | Average non-PEO NEO SCT to CAP Reconciliation Fiscal Year Average Reported Total for non-PEO Average Reported Average Equity Average Compensation Actually Paid to non-PEO 2022 $ 3,393,116 $ (2,640,104 ) $ 198,549 $ 951,561 2021 $ 2,469,172 $ (1,539,799 ) $ (736,691 ) $ 192,682 2020 $ 2,457,336 $ (1,406,360 ) $ 3,984,107 $ 5,035,083 Average non-PEO NEO Equity Award Adjustment Reconciliation Fiscal Year Average Year-End Fair Year-over-Year Equity Awards Vesting Date Year-over-Year Average Average Value of Total Average 2022 $ 764,901 $ (389,222 ) $ — $ (177,130 ) $ — $ — $ 198,549 2021 $ 575,964 $ (1,417,932 ) $ — $ 105,276 $ — $ — $ (736,691 ) 2020 $ 2,391,709 $ 1,136,285 $ — $ 456,113 $ — $ — $ 3,984,107 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | |||
| Compensation Actually Paid vs. Net Income [Text Block] | |||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||
| Total Shareholder Return Vs Peer Group [Text Block] | |||
| Tabular List [Table Text Block] | Financial Performance Measures The following table lists the three financial performance measures that, in Emergent’s assessment, are the most important measures that the company uses to link CAP to its NEOs to company performance. The following is provided in accordance with Item 402(v) of Regulation S-K. Measure 1 Total Revenues Measure 2 Adjusted EBITDA Margin Measure 3 Adjusted Net Income (Loss) | ||
| Total Shareholder Return Amount | $ 21.89 | 80.57 | 166.08 |
| Peer Group Total Shareholder Return Amount | 140.85 | 121.8 | 108.63 |
| Net Income (Loss) | $ (223,800,000) | $ 230,900,000 | $ 305,100,000 |
| Company Selected Measure Amount | 1,120,900,000 | 1,792,700,000 | 1,555,400,000 |
| PEO Name | Mr. Kramer | ||
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Total Revenues | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted EBITDA Margin | ||
| Measure [Axis]: 3 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted Net Income (Loss) | ||
| PEO [Member] | Reported Value of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (6,231,882) | $ (4,998,767) | $ (3,442,423) |
| PEO [Member] | Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (838,421) | (1,400,921) | 8,096,411 |
| PEO [Member] | YearEnd Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,391,610 | 1,869,759 | 5,854,355 |
| PEO [Member] | YearoverYear Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,603,115) | (3,301,247) | 1,898,642 |
| PEO [Member] | Yearover Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (626,916) | 30,567 | 343,414 |
| Non-PEO NEO [Member] | Reported Value of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (2,640,104) | (1,539,799) | (1,406,360) |
| Non-PEO NEO [Member] | Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 198,549 | (736,691) | 3,984,107 |
| Non-PEO NEO [Member] | YearEnd Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 764,901 | 575,964 | 2,391,709 |
| Non-PEO NEO [Member] | YearoverYear Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (389,222) | (1,417,932) | 1,136,285 |
| Non-PEO NEO [Member] | Yearover Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (177,130) | $ 105,276 | $ 456,113 |
